Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials ...

In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal genetic data. What to know ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

Regeneron Pharmaceuticals (REGN) shares dropped nearly 10% in premarket trading Friday after mixed results from late-stage ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to Regeneron Pharmaceuticals, the acquisition includes 23andMe's Personal ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...